Press Releases

Date Title and Summary Additional Formats
Toggle Summary Anthera and Patheon Sign Manufacturing Agreement for Liprotamase Phase III Registration Trial View HTML
Toggle Summary Anthera Announces $3 Million Research Award from Cystic Fibrosis Foundation Therapeutics for Development of Sollpura - a Novel Enzyme Therapy View HTML
Toggle Summary Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting View HTML
Toggle Summary Anthera Announces Completion of Dosing in the Phase 2 BRIGHT-SC Study of Blisibimod in Patients with IgA Nephropathy View HTML
Toggle Summary Anthera Announces Completion of Enrollment and Dosing In Phase II Trial of A-002 for the Treatment of Cardiovascular Disease View HTML
Toggle Summary Anthera Announces Completion of Safety Review by DSMB for VISTA-16
-Enrollment In VISTA-16 Continues Without Modification
View HTML
Toggle Summary Anthera Announces Conference Call to Discuss Analytical Method and Timing of Upcoming VISTA-16 Biomarker Analysis View HTML
Toggle Summary Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit View HTML
Toggle Summary Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus View HTML
Toggle Summary Anthera Announces Enrollment Of 500th Patient In Francis Trial Of A-002 For The Treatment Of Cardiovascular Disease View HTML